MDGL

SEC source: 0000950170-24-078756 · ownership.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 375,076

F1 · shares: Represents a grant of restricted stock units, which vest on June 25, 2025, provided the Reporting Person continues in service with the Issuer on such date.

SEC source: 0000950170-24-078565 · ownership.xml · derivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,210

Underlying: Common Stock · 2,210 shares

Expires 2031-06-25

F10 · shares: Includes 1,105 Stock Options granted by the Issuer to each of Julian C. Baker and Dr. Cheong on June 25, 2024, pursuant to the 2015 Plan. The Stock Options have a strike price of $280.04, fully vest on the first anniversary of the grant date subject to the applicable director's continuous service on the Board through the vesting date. and expire 7 years from the date of grant.

F10 · derivative.exercise_date: Includes 1,105 Stock Options granted by the Issuer to each of Julian C. Baker and Dr. Cheong on June 25, 2024, pursuant to the 2015 Plan. The Stock Options have a strike price of $280.04, fully vest on the first anniversary of the grant date subject to the applicable director's continuous service on the Board through the vesting date. and expire 7 years from the date of grant.

F3 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock ("Stock Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F7 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to each of Julian C. Baker and Dr. Cheong of 714 RSUs on Table I and 1,105 Stock Options on Table II. These grants, totaling 1,428 RSUs and 2,210 Stock Options for Julian C. Baker and Dr. Cheong in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F9 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-24-078565 · ownership.xml · derivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,210

Underlying: Common Stock · 2,210 shares

Expires 2031-06-25

F10 · shares: Includes 1,105 Stock Options granted by the Issuer to each of Julian C. Baker and Dr. Cheong on June 25, 2024, pursuant to the 2015 Plan. The Stock Options have a strike price of $280.04, fully vest on the first anniversary of the grant date subject to the applicable director's continuous service on the Board through the vesting date. and expire 7 years from the date of grant.

F10 · derivative.exercise_date: Includes 1,105 Stock Options granted by the Issuer to each of Julian C. Baker and Dr. Cheong on June 25, 2024, pursuant to the 2015 Plan. The Stock Options have a strike price of $280.04, fully vest on the first anniversary of the grant date subject to the applicable director's continuous service on the Board through the vesting date. and expire 7 years from the date of grant.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock ("Stock Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F7 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to each of Julian C. Baker and Dr. Cheong of 714 RSUs on Table I and 1,105 Stock Options on Table II. These grants, totaling 1,428 RSUs and 2,210 Stock Options for Julian C. Baker and Dr. Cheong in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0000950170-24-078565 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,794,831

F1 · shares: Includes 714 restricted stock units (each an "RSU") payable solely in common stock ("Common Stock") granted by Madrigal Pharmaceuticals, Inc. (the "Issuer") to each of Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP"), and Dr. Raymond Cheong, an employee of Baker Bros. Advisors LP (the "Adviser"), on June 25, 2024, pursuant to the Issuer's Amended 2015 Stock Plan (the "2015 Plan"). The RSUs fully vest on the first anniversary of the grant date subject to the applicable director's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Julian C. Baker and Dr. Cheong serve on the Board as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock ("Stock Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F7 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to each of Julian C. Baker and Dr. Cheong of 714 RSUs on Table I and 1,105 Stock Options on Table II. These grants, totaling 1,428 RSUs and 2,210 Stock Options for Julian C. Baker and Dr. Cheong in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F8 · ownership.nature: Includes beneficial ownership of 2,396 shares of Common Stock received from vested RSUs each previously granted to Julian C. Baker and Dr. Cheong in their capacity as directors of the Issuer.

F9 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-24-078565 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 187,407

F1 · shares: Includes 714 restricted stock units (each an "RSU") payable solely in common stock ("Common Stock") granted by Madrigal Pharmaceuticals, Inc. (the "Issuer") to each of Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP"), and Dr. Raymond Cheong, an employee of Baker Bros. Advisors LP (the "Adviser"), on June 25, 2024, pursuant to the Issuer's Amended 2015 Stock Plan (the "2015 Plan"). The RSUs fully vest on the first anniversary of the grant date subject to the applicable director's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Julian C. Baker and Dr. Cheong serve on the Board as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock ("Stock Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board Service.

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F7 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to each of Julian C. Baker and Dr. Cheong of 714 RSUs on Table I and 1,105 Stock Options on Table II. These grants, totaling 1,428 RSUs and 2,210 Stock Options for Julian C. Baker and Dr. Cheong in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F8 · ownership.nature: Includes beneficial ownership of 2,396 shares of Common Stock received from vested RSUs each previously granted to Julian C. Baker and Dr. Cheong in their capacity as directors of the Issuer.

SEC source: 0000950170-24-078754 · ownership.xml · derivative · entry 2

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,105

Underlying: Common Stock · 1,105 shares

Expires 2031-06-25

F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.

SEC source: 0000950170-24-078754 · ownership.xml · nonDerivative · entry 1

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,912

F1 · shares: Represents a grant of restricted stock units, which vest on June 25, 2025, provided the Reporting Person continues in service with the Issuer on such date.

SEC source: 0000950170-24-078750 · ownership.xml · derivative · entry 2

Daly James M · CIK 0001560782 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,105

Underlying: Common Stock · 1,105 shares

Expires 2031-06-25

F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.

SEC source: 0000950170-24-078750 · ownership.xml · nonDerivative · entry 1

Daly James M · CIK 0001560782 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,912

F1 · shares: Represents a grant of restricted stock units, which vest on June 25, 2025, provided the Reporting Person continues in service with the Issuer on such date.

SEC source: 0000950170-24-078749 · ownership.xml · derivative · entry 2

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,105

Underlying: Common Stock · 1,105 shares

Expires 2031-06-25

F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.

SEC source: 0000950170-24-078749 · ownership.xml · nonDerivative · entry 1

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,012

F1 · shares: Represents a grant of restricted stock units, which vest on June 25, 2025, provided the Reporting Person continues in service with the Issuer on such date.

SEC source: 0000950170-24-078748 · ownership.xml · derivative · entry 3

FRIEDMAN PAUL A · CIK 0001236927 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,105

Underlying: Common Stock · 1,105 shares

Expires 2031-06-25

F3 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.

SEC source: 0000950170-24-078748 · ownership.xml · nonDerivative · entry 1

FRIEDMAN PAUL A · CIK 0001236927 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,449

F1 · shares: Represents a grant of restricted stock units, which vest on June 25, 2025, provided the Reporting Person continues in service with the Issuer on such date.

SEC source: 0000950170-24-075221 · ownership.xml · derivative · entry 3

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,350

Underlying: Common Stock · Not disclosed shares

Expires 2032-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: All shares issued pursuant to the exercise of the options reported herein represent 1,900 shares underlying an overall option award of 12,250 shares. All exercised options had vested. As to the overall option for 12,250 shares, 25% of the shares underlying the option vested on February 24, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0000950170-24-075221 · ownership.xml · nonDerivative · entry 2

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

SEC source: 0000950170-24-075221 · ownership.xml · nonDerivative · entry 1

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All shares issued pursuant to the exercise of the options reported herein represent 1,900 shares underlying an overall option award of 12,250 shares. All exercised options had vested. As to the overall option for 12,250 shares, 25% of the shares underlying the option vested on February 24, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0000950170-24-073969 · ownership.xml · derivative · entry 3

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,200

Underlying: Common Stock · 2,000 shares

Expires 2031-08-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: All shares issued pursuant to the exercise of the options reported herein represent 2,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0000950170-24-073969 · ownership.xml · nonDerivative · entry 2

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

SEC source: 0000950170-24-073969 · ownership.xml · nonDerivative · entry 1

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All shares issued pursuant to the exercise of the options reported herein represent 2,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0000950170-24-073290 · ownership.xml · nonDerivative · entry 2

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 11,210

F1 · ownership.nature: Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust.

SEC source: 0000950170-24-073290 · ownership.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 374,362

SEC source: 0000950170-24-064271 · ownership.xml · nonDerivative · entry 1

Waltermire Robert E. · CIK 0001876996 · Senior VP, Chief Pharma Dev.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

SEC source: 0000950170-24-061321 · ownership.xml · derivative · entry 17

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,489 shares

Expires 2024-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F14 · derivative.exercise_date: The shares underlying this stock option are fully vested.

SEC source: 0000950170-24-061321 · ownership.xml · derivative · entry 16

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2024-06-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F14 · derivative.exercise_date: The shares underlying this stock option are fully vested.

SEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 12

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 413,362

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.

SEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 11

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 413,462

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.68 to $219.34 inclusive.

SEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 10

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 414,462

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.64 to $218.37 inclusive.

SEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 9

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 415,562

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.61 to $217.23 inclusive.

SEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 8

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 416,283

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.61 to $216.58 inclusive.

SEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 7

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 416,658

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.39 to $215.27 inclusive.

SEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 6

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 418,462

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.36 to $214.34 inclusive.

SEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 5

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 420,652

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.36 to $213.31 inclusive.

SEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 4

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 422,015

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.34 to $212.33, inclusive.

SEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 3

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 427,024

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.34 to $211.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

SEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 2

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 435,851

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-061321 · ownership.xml · nonDerivative · entry 1

CRAVES FRED B · CIK 0001014095 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 423,362

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-043503 · ownership.xml · derivative · entry 9

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,564

Underlying: Common Stock · 2,676 shares

Expires 2026-07-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable.

SEC source: 0000950170-24-043503 · ownership.xml · nonDerivative · entry 7

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 458,999

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.57 to $248.59, inclusive.

SEC source: 0000950170-24-043503 · ownership.xml · nonDerivative · entry 6

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 459,199

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.56 to $248.5150, inclusive.

SEC source: 0000950170-24-043503 · ownership.xml · nonDerivative · entry 5

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 459,606

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.50 to $247.25, inclusive.

SEC source: 0000950170-24-043503 · ownership.xml · nonDerivative · entry 4

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 460,206

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.38 to $246.13, inclusive.

SEC source: 0000950170-24-043503 · ownership.xml · nonDerivative · entry 3

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 460,506

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.37 to $245.24, inclusive.

SEC source: 0000950170-24-043503 · ownership.xml · nonDerivative · entry 2

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 461,451

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.12 to $243.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

SEC source: 0000950170-24-043503 · ownership.xml · nonDerivative · entry 1

Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 461,675

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-043502 · ownership.xml · derivative · entry 10

FRIEDMAN PAUL A · CIK 0001236927 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 206,256

Underlying: Common Stock · 26,270 shares

Expires 2026-07-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable.

SEC source: 0000950170-24-043502 · ownership.xml · nonDerivative · entry 8

FRIEDMAN PAUL A · CIK 0001236927 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 185,735

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.47 to $248.64, inclusive.

SEC source: 0000950170-24-043502 · ownership.xml · nonDerivative · entry 7

FRIEDMAN PAUL A · CIK 0001236927 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 190,601

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.47 to $248.24, inclusive.

SEC source: 0000950170-24-043502 · ownership.xml · nonDerivative · entry 6

FRIEDMAN PAUL A · CIK 0001236927 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 194,065

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.45 to $247.43, inclusive.

SEC source: 0000950170-24-043502 · ownership.xml · nonDerivative · entry 5

FRIEDMAN PAUL A · CIK 0001236927 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 199,093

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.43 to $246.28, inclusive.

SEC source: 0000950170-24-043502 · ownership.xml · nonDerivative · entry 4

FRIEDMAN PAUL A · CIK 0001236927 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 201,171

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.43 to $245.42, inclusive.